Glycation gap is associated with macroproteinuria but not with other complications in patients with type 2 diabetes

Diabetes Care

Volumn 36, Issue 7, 2013, Pages 2070-2076

  Cosson, Emmanuel ^a   Banu, Isabela ^a   Cussac Pillegand, Camille ^a   Chen, Qinda ^a,b   Chiheb, Sabrina ^a   Jaber, Yahya ^a   Nguyen, Minh Tuan ^a   Charnaux, Nathalie ^a   Valensi, Paul ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b Shanghai Clinical Center for Endocrine and Metabolic Diseases   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; FRUCTOSAMINE; HEMOGLOBIN A1C;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; AUTONOMIC NEUROPATHY; CARDIAC AUTONOMIC NEUROPATHY; CELLULAR PARAMETERS; COHORT ANALYSIS; COMPLICATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DYSLIPIDEMIA; FEMALE; FRUCTOSAMINE BLOOD LEVEL; GLYCATION GAP; GLYCEMIC CONTROL; HEART DISEASE; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; MACROPROTEINURIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PREDICTION; PREVALENCE; PROTEIN GLYCOSYLATION; PROTEINURIA; SEX RATIO; SILENT MYOCARDIAL ISCHEMIA;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FRUCTOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PROTEINURIA;

EID: 84882660231     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1780     Document Type: Article

References (25)

1. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ; A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008; 31:1473-1478
2. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002;25:275-278
3. Hempe JM, Gomez R, McCarter RJ Jr, Chalew SA. High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complications 2002; 16:313-320
4. Cohen RM, Holmes YR, Chenier TC, Joiner CH. Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy. Diabetes Care 2003;26:163-167
5. Rodríguez-Segade S, Rodríguez J, Cabezas- Agricola JM, Casanueva FF, Camiña F. Progression of nephropathy in type 2 diabetes: the glycation gap is a significant predictor after adjustment for glycohemoglobin (HbA1c). Clin Chem 2011;57: 264-271
6. Nayak AU, Holland MR, Macdonald DR, Nevill A, Singh BM. Evidence for consistency of the glycation gap in diabetes. Diabetes Care 2011;34:1712-1716
7. Cohen RM, LeCaire TJ, Lindsell CJ, Smith EP, D'Alessio DJ. Relationship of prospective GHb to glycated serum proteins in incident diabetic retinopathy: implications of the glycation gap for mechanism of risk prediction. Diabetes Care 2008;31:151-153
8. MittmanN,Desiraju B, Fazil I., et al. Serum fructosamine versus glycosylated hemoglobin as an index of glycemic control, hospitalization, and infection in diabetic hemodialysis patients. Kidney Int Suppl 2010;117:S41-S45
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470
10. Spallone V, Ziegler D, Freeman R., et al., on behalf of the Toronto Consensus Panel on Diabetic Neuropathy. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 2011;27:639-653
11. Valensi P, Pariès J, Attali JR; French Group for Research and Study of Diabetic Neuropathy. Cardiac autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and microangiopathic complicationsdthe French multicenter study. Metabolism 2003;52:815-820
12. Cosson E, Guimfack M, Paries J, Paycha F, Attali JR, Valensi P. Prognosis for coronary stenoses in patients with diabetes and silent myocardial ischemia. Diabetes Care 2003;26:1313-1314
13. Cosson E, Guimfack M, Paries J, Paycha F, Attali JR, Valensi P. Are silent coronary stenoses predictable in diabetic patients and predictive of cardiovascular events? Diabetes Metab 2003;29:470-476
14. Cosson E, Nguyen MT, Pham I, Pontet M, Nitenberg A, Valensi P. N-terminal pro-Btype natriuretic peptide: an independent marker for coronary artery disease in asymptomatic diabetic patients. Diabet Med 2009;26:872-879
15. Cosson E, Nguyen MT, Chanu B, Balta S, Takbou K, Valensi P. The report of male gender and retinopathy status improves the current consensus guidelines for the screening of myocardial ischemia in asymptomatic type 2 diabetic patients. Nutr Metab Cardiovasc Dis 12 April 2012 [Epub ahead of print]
16. Cosson E,NguyenMT, Hamo-Tchatchouang E., et al. What would be the outcome if the American Diabetes Association recommendations of 2010 had been followed in our practice in 1998-2006? Diabet Med 2011;28:567-574
17. Cefalu WT, Bell-Farrow AD, PettyM, Izlar C, Smith JA. Clinical validation of a second-generation fructosamine assay. Clin Chem 1991;37:1252-1256
18. Van Dieijen-Visser MP, Seynaeve C, Brombacher PJ. Influence of variations in albumin or total-protein concentration on serum fructosamine concentration. Clin Chem 1986;32:1610
19. Lamb E, Venton TR, Cattell WR, Dawnay A. Serumglycated albumin and fructosamine in renal dialysis patients. Nephron 1993;64: 82-88
20. McCarter RJ, Hempe JM, Gomez R, Chalew SA. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care 2004;27: 1259-1264
21. Lachin JM, Genuth S, Nathan DM, Rutledge BN. The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial. Diabetes 2007;56:1913-1921
22. Gould BJ, Davie SJ, Yudkin JS. Investigation of the mechanism underlying the variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Clin Chim Acta 1997;260: 49-64
23. Bent-Hansen L, Feldt-Rasmussen B, Kverneland A, Deckert T. Plasma disappearance of glycated and non-glycated albumin in type 1 (insulin-dependent) diabetes mellitus: evidence for charge dependent alterations of the plasma to lymph pathway. Diabetologia 1993;36: 361-363
24. Cohen RM, Snieder H, Lindsell CJ., et al. Evidence for independent heritability of the glycation gap (glycosylation gap) fraction of HbA1c in nondiabetic twins. Diabetes Care 2006;29:1739-1743
25. Leslie RD, Cohen RM. Biologic variability in plasma glucose, hemoglobin A1c, and advanced glycation end products associated with diabetes complications. J Diabetes Sci Tech 2009;3: 635-643